Evaluation of Dimebon in cellular model of Huntington's disease

Springer Science and Business Media LLC - Tập 3 Số 1 - 2008
Jun Wu1, Qin Li1, Ilya Bezprozvanny1
1Department of Physiology, UT Southwestern Medical Center at Dallas, TX, 75390, USA

Tóm tắt

Abstract Background Dimebon is an antihistamine compound with a long history of clinical use in Russia. Recently, Dimebon has been proposed to be useful for treating neurodegenerative disorders. It has demonstrated efficacy in phase II Alzheimer's disease (AD) and Huntington's disease (HD) clinical trials. The mechanisms responsible for the beneficial actions of Dimebon in AD and HD remain unclear. It has been suggested that Dimebon may act by blocking NMDA receptors or voltage-gated Ca2+ channels and by preventing mitochondrial permeability pore transition. Results We evaluated the effects of Dimebon in experiments with primary striatal neuronal cultures (MSN) from wild type (WT) mice and YAC128 HD transgenic mice. We found that Dimebon acts as an inhibitor of NMDA receptors (IC50 = 10 μM) and voltage-gated calcium channels (IC50 = 50 μM) in WT and YAC128 MSN. We further found that application of 50 μM Dimebon stabilized glutamate-induced Ca2+ signals in YAC128 MSN and protected cultured YAC128 MSN from glutamate-induced apoptosis. Lower concentrations of Dimebon (5 μM and 10 μM) did not stabilize glutamate-induced Ca2+ signals and did not exert neuroprotective effects in experiments with YAC128 MSN. Evaluation of Dimebon against a set of biochemical targets indicated that Dimebon inhibits α-Adrenergic receptors (α1A, α1B, α1D, and α2A), Histamine H1 and H2 receptors and Serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors with high affinity. Dimebon also had significant effect on a number of additional receptors. Conclusion Our results suggest that Ca2+ and mitochondria stabilizing effects may, in part, be responsible for beneficial clinical effects of Dimebon. However, the high concentrations of Dimebon required to achieve Ca2+ stabilizing and neuroprotective effects in our in vitro studies (50 μM) indicate that properties of Dimebon as cognitive enhancer are most likely due to potent inhibition of H1 histamine receptors. It is also possible that Dimebon acts on novel high affinity targets not present in cultured MSN preparation. Unbiased evaluation of Dimebon against a set of biochemical targets indicated that Dimebon efficiently inhibited a number of additional receptors. Potential interactions with these receptors need to be considered in interpretation of results obtained with Dimebon in clinical trials.

Từ khóa


Tài liệu tham khảo

Vonsattel JP, DiFiglia M: Huntington disease. J Neuropathol Exp Neurol. 1998, 57: 369-84. 10.1097/00005072-199805000-00001.

The Huntington's Disease Collaborative Research and Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72: 971-83. 10.1016/0092-8674(93)90585-E.

Tobin AJ, Signer ER: Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 2000, 10: 531-6. 10.1016/S0962-8924(00)01853-5.

Bezprozvanny I, Hayden MR: Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun. 2004, 322: 1310-7. 10.1016/j.bbrc.2004.08.035.

Khachaturian ZS: Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci. 1989, 568: 1-4. 10.1111/j.1749-6632.1989.tb12485.x.

Bezprozvanny I, Mattson MP: Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31 (9): 454-463. 10.1016/j.tins.2008.06.005.

Bachurin S, et al: Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci. 2001, 939: 425-35.

Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-15. 10.1016/S0140-6736(08)61074-0.

Grigorev VV, Dranyi OA, Bachurin SO: Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med. 2003, 136: 474-7. 10.1023/B:BEBM.0000017097.75818.14.

Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO: Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med. 2001, 132: 1079-83. 10.1023/A:1017972709652.

Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO: Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003, 993: 334-44.

Tang T-S, et al: Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci USA. 2005, 102: 2602-2607. 10.1073/pnas.0409402102.

Wu J, Tang T-S, Bezprozvanny I: Evaluation of clinically-relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci Lett. 2006, 407: 219-223. 10.1016/j.neulet.2006.08.036.

Tang TS, Chen X, Liu J, Bezprozvanny I: Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci. 2007, 27: 7899-910. 10.1523/JNEUROSCI.1396-07.2007.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I: Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis. 2008, 31: 80-8. 10.1016/j.nbd.2008.03.010.

Tang T-S, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I: Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 2003, 39: 227-239. 10.1016/S0896-6273(03)00366-0.

Bargas J, Howe A, Eberwine J, Cao Y, Surmeier DJ: Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons. J Neurosci. 1994, 14: 6667-86.

Milnerwood AJ, Raymond LA: Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol. 2007, 585: 817-31. 10.1113/jphysiol.2007.142448.

Hung D: HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE. WO/2007/041697, USA. 2007

Stavrovskaya IG, et al: Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med. 2004, 200: 211-22. 10.1084/jem.20032053.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 3 Số 1

Thông tin tác giả